Custom engineering services, scalable transient and stable cell line solutions.
Lentivirus at the edge of impossible
OXGENE has re-developed the lentiviral plasmid system to facilitate yields greater than 1x10⁸ TU/ml, and generated manufacture-ready suspension-mode lentiviral packaging cell lines to facilitate large scale lentiviral production. This system maximizes process reproducibility and reduces manufacturing costs for some of the industry’s most exciting therapies.
Lentiviral Transient System
OXGENE has optimised its 3rd generation, self-inactivating (SIN) lentivirus packaging plasmids to improve safety, reduce homology and increase yield. Each plasmid is built on an optimized and minimized backbone after multiple screening experiments to identify ideal configurations and stoichiometries. This generates a well-characterized, high-titre lentiviral system that outperforms all other commercially available equivalents in our proprietary serum-free, suspension HEK293 cell line.
Our plasmids are immediately available for evaluation purposes and can also be accessed through our technology partner Aldevron. We can also customise this system to clone any gene of interest, or for novel/non-standard pseudotyping.
Our transient lentiviral expression platform transitions seamlessly to a stable lentiviral packaging cell line, which allows for single plasmid transfection, and so reduces process complexity and cost of goods, and simplifies the supply chain.
Lentiviral Packaging and Producer Cell Lines
OXGENE has successfully developed a suspension-mode, stable lentiviral packaging cell line platform using a proprietary Tet-inducible system. This demonstrates high titre lentiviral production with single plasmid transfection in both shake flask and bioreactor.
Our packaging cell lines also form the basis of our GMP-compliant, animal component free producer cell lines, which permit transfection-free, large-scale production of lentiviral vectors for cell and gene therapies.
We used a fully-defined, serum/animal component-free process to generate both our packaging and producer GMP-compliant HEK293 cell lines. Cell lines do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.
Genetic medicine has experienced tremendous growth with the approval of multiple products that dramatically improve life. Lentiviral vectors are the key component for manufacturing many of these treatments. The free availability of lentiviral packaging plasmids will significantly reduce the time and cost to develop and commercialize these products.